Who we are ….
Our Leadership
Kevin Slawin, M.D. is the Founder and CEO at Eos SENOLYTIX, Inc., a gerotherapeutics company whose lead programs are focused on proprietary senolytic peptides, that may restore the youthful balance of aged or “senescent” and young cells throughout the organs of the body. He is also the Founder and CEO of Phoenix SENOLYTIX, Inc., a longevity company developing novel gene therapies targeting senescent cells, among other fundamental mechanisms of aging. He was the co-founder of Bellicum Pharmaceuticals, Inc., leading Bellicum to a successful $161 million IPO in December, 2014. He is also Founder, Chairman and CEO of PrintBio, Inc., the only clinical- and commercial-stage regenerative medicine company solving medical challenges with custom-engineered 3D-bioprinted living implants. He currently lives in Miami, FL where he is Founder and CEO of Miami Medicos, a membership organization of physicians, founders, executives, and investors catalyzing the healthcare entrepreneurial ecosystem in Miami and worldwide.
Jodi Akin, MSN is Acting Chief, Clinical Strategy and Regulatory Affairs at Eos SENOLYTIX, Inc. With over 35 years of experience as an entrepreneur and executive in the life sciences sector, Jodi has held pivotal leadership roles in both public and private companies, spearheading transformative technologies and therapies. Throughout her career, she has brought numerous products to market, achieving global adoption and market leadership. Most recently, Jodi served as the Founding Chief Executive Officer of Hawthorne Health, a pioneering platform aimed at improving patient access to clinical trials and enhancing the quality and diversity of clinical trial programs. Under her stewardship, Hawthorne advanced from concept to commercialization and established a strategic partnership with LabCorp, Inc., becoming a leader in decentralized clinical trials. In 2006, Jodi joined Edwards Lifesciences, LLC as Vice President of Global Clinical Affairs, leading critical global clinical trials for transcatheter heart valve therapy and fostering collaboration between cardiac surgeons and cardiologists through the PARTNER trials. Her work culminated in the FDA approval of the SAPIEN Transcatheter Heart Valve, establishing new standards in heart valve therapy and clinical trial methodologies. Throughout her career, Jodi founded three companies, raised over $120 million in venture capital, led strategic partnerships, and participated in IPOs as well as mergers and acquisitions.
Kayvon Namar is the CFO at Eos SENOLYTIX, Inc. He has deep expertise in forecasting, valuation, litigation support, and transaction advisory support. In life sciences, Kayvon has developed dynamic patient-flow and other financial models to facilitate the forecasting and valuation of biopharmaceutical, medical device and diagnostic products, companies, complex securities, and royalty interests for transaction, bankruptcy, tax, and accounting oriented purposes. Kayvon has worked with companies ranging from large, publicly traded entities, to small, venture capital-backed organizations.
Kayvon is Founder and Manager of Lookout Ridge Capital Advisors. Previously, he served as a Principal at RNA Capital Advisors, a financial and strategic advisory firm, and as VP, Finance & Strategic Analysis at Hawthorne Effect, Inc, a healthcare technology company focused on decentralizing clinical trials. Previously, Kayvon was a director in the consulting group at Burr Pilger Mayer, Inc., a consulting and accounting firm headquartered in San Francisco. Kayvon was also a director in the valuation and financial advisory services group within the corporate finance and restructuring division of FTI Consulting, Inc. His predecessor company, The Salter Group, LLC, a leading independent financial and strategic advisory firm, was acquired by FTI.
Kayvon holds a Bachelor of Science degree in Business Administration with a concentration in Corporate Finance from the University of Southern California. He has been a guest lecturer and presenter at the University of Southern California and the California Institute of Technology, among others.
Daniel Jasinski, Ph.D. is the Vice President of Research at Eos SENOLYTIX, Inc. Previously, he held the position of Director of Research at Ponce Therapeutics, Inc. Prior to that , he was Research Scientist at Bellicum Pharmaceuticals, where he worked for 4 years until 2021. Dr. Jasinski earned his Ph.D. in Pharmaceutical Sciences from the University of Kentucky’s College of Pharmacy. His past innovative research has been published in several prestigious scientific journals including Blood, Advanced Materials, and Nucleic Acids Research. Passionate about translating scientific discoveries into real-world applications, Dr. Jasinski is committed to advancing the frontiers of Longevity Medicine
Frank McGuyer is chairman, CEO, and co-founder of Houston based McGuyer Homebuilders (MHI). Earlier in his career, McGuyer worked for one-time public home builder General Homes for about 14 years. Today, MHI operates exclusively in four Texas markets, posting a record 3,450 closings in 2006. Frank served on the board of directors of Bellicum Pharmaceuticals for nine years, resigning at the end of 2018.
Kevin Slawin, M.D. is the Founder and CEO at Eos SENOLYTIX, Inc., a gerotherapeutics company whose lead programs are focused on proprietary senolytic peptides, that may restore the youthful balance of aged or “senescent” and young cells throughout the organs of the body. He is also the Founder and CEO of Phoenix SENOLYTIX, Inc., a longevity company developing novel gene therapies targeting senescent cells, among other fundamental mechanisms of aging. He was the co-founder of Bellicum Pharmaceuticals, Inc., leading Bellicum to a successful $161 million IPO in December, 2014. He is also Founder, Chairman and CEO of PrintBio, Inc., the only clinical- and commercial-stage regenerative medicine company solving medical challenges with custom-engineered 3D-bioprinted living implants. He currently lives in Miami, FL where he is Founder and CEO of Miami Medicos, a membership organization of physicians, founders, executives, and investors catalyzing the healthcare entrepreneurial ecosystem in Miami and worldwide.
He is also the founder and CEO of Ponce Therapeutics, Inc. (https://poncetherapeutics.com), which reunites the team that founded Bellicum Pharmaceuticals and that is using advanced technologies to develop novel therapeutics targeting the fundamental mechanisms of aging, and DELiver Therapeutics, Inc. (https://delivertherapeutics.com), which is applying high throughput DNA encoded library (DEL) drug screening combined with other advanced technologies in novel ways to deliver small molecule and peptide therapeutics that address some of the most challenging and, some previously termed “undruggable”, targets in clinical medicine. Both have R&D facilities located at K2Bio in Houston (https://www.k2-biolabs.com/), a coworking research facility for biotech and pharma startups recently opened in Houston, where he is a co-founder, investor, and board member. He is also the Founder, Chairman and CEO of PrintBio, Inc. (https://senothera.wpenginepowered.com), a commercial stage company with products powered by advanced bio-printing technologies.
Slawin graduated magna cum laude with a Bachelor of Arts degree in Biochemistry from Columbia University, where he was inducted into Phi Beta Kappa. He earned his medical degree in 1986 from Columbia College of Physicians and Surgeons and was elected to the Alpha Omega Alpha honor society. He trained in General Surgery and then Urology at the Mount Sinai Hospital and at Squier Urologic Clinic at Columbia Presbyterian Hospital, both in NYC. Later, he was awarded a two-year fellowship, from 1992-1994, as an American Foundation of Urologic Disease (AFUD) scholar at Baylor College of Medicine to continue to study the development and treatment of prostate cancer under the tutelage of renowned prostate cancer surgeon and thought leader, Dr. Peter Scardino. Slawin joined the Baylor College of Medicine as Director of The Baylor Prostate Center in 1994 and was appointed the Dan Duncan Family Professor in Prostate Cancer and Prostatic Diseases in 2003, established by the well-known Houston oil man and philanthropist of the same name. He is co-Inventor of the FDA-approved “prostate health index (phi)” test licensed and marketed by Beckman Coulter and utilized around the world. He has published extensively in top medical and scientific journals including the Journal of the American Medical Association (JAMA), Journal of the National Cancer Institute (JNCI), and the New England Journal of Medicine (NEJM). He has also been routinely listed in America’s Top Doctors for Cancer (Castle Connolly Medical) and The Best Doctors in America (Woodward/White). In 2003, he was awarded the F. Brantley Scott, Jr., Award for Innovation and Creativity in Urology. He currently lives in Miami, FL where he is Founder and CEO of Miami Medicos (https://miamimedicos.com), a membership organization of physicians, founders, executives, and investors catalyzing the healthcare entrepreneurial ecosystem in Miami and worldwide.
Jerry Winograd is the co-managing partner of Judwin Realty Group, LLC (JRG) and its affiliates. JRG maintains a dual focus on new multi-family development within master-planned communities and the redevelopment of distressed multi-family properties. Additionally, JRG self-manages its entire real estate portfolio.
Jerry currently serves on the board of directors of the Houston Apartment Association, having served as its President in 2006. He joined the board of the Texas Apartment Association in 2001, eventually serving as President from 2010–2011, and is a past president of the Texas Apartment Association Education Foundation. Since 2004, Jerry has been a member of the assembly of delegates for the National Apartment Association. Furthermore, he serves on the board of Briar Capital, a Houston-based lender, and on the Development Board of the University of Texas Medical Branch.
From 2013 to 2021, Jerry served as an associate lecturer for the Multifamily Residential Real Estate Fundamentals MBA course at the University of Houston
Brent Saunders is a visionary leader and one of the most successful value creators in the history of health care. As the CEO and Chairman of Bausch+Lomb, Brent oversees a team of approximately 13,000 people who deliver innovative solutions to protect and enhance the gift of sight for millions of individuals worldwide.
He has been the driving force behind numerous health care and pharmaceutical mega deals that have resulted in tremendous benefits for patients, shareholders and employees. These include Allergan plc.’s $63 billion acquisition by Abbvie Inc, Forest Laboratories Inc.’s $25 billion merger with Actavis plc and Actavis’ $66 billion acquisition of Allergan.
Brent is a sought-after advisor and industry thought leader. He has served on the boards of companies ranging from early-stage innovators to established brands including Cisco Systems, Inc. He currently serves as the Chairman of the Board of The Beauty Health Company, a director of ARS Pharmaceuticals, Inc. and Arena AI, and as a board advisor to Nextech. He is also on the
Executive Committee of Mt. Sinai Medical Center.
Howard L. Morgan is Chair and General Partner at B Capital, where he brings more than four decades of leadership in venture capital, quantitative finance, and technology innovation. He is widely recognized as a pioneer of early‑stage investing and an influential figure in the development of the early internet.
Dr. Morgan co‑founded First Round Capital, one of the most prominent early‑stage venture firms in the United States, and served as the Founding President of Renaissance Technologies, the quantitative hedge fund that became an industry landmark. His academic research in user interface design and computer network optimization played a critical role in bringing the ARPANET—the precursor to the modern internet—to Philadelphia in the 1970s.
Before entering the private sector full‑time, Dr. Morgan held faculty appointments at Cornell University, The Wharton School, and the University of Pennsylvania, where he taught operations research, computer science, and decision sciences. He also served as the first Editor of the ACM Transactions on Database Systems, reflecting his deep expertise in large‑scale data systems.
In addition to his role at B Capital, Dr. Morgan has served as chairman, director, or advisor to numerous technology companies and nonprofit organizations, contributing to innovation across sectors including AI, data science, and advanced computing.
Dr. Morgan holds a BS in Physics from the City College of New York and a PhD in Operations Research from Cornell University.
Dr. Nir Barzilai is the director of the Institute for Aging Research at the Albert Einstein College of Medicine. He is also the Scientific Director and on the board of the American Federation for Aging Research. He is the Executive Director of the Longevity Biotech Association (LBA). He is the Director of the Paul F. Glenn Center for the Biology of Human Aging Research and of the National Institutes of Health’s (NIH) Nathan Shock Centers of Excellence in the Basic Biology of Aging. He is the Ingeborg and Ira Leon Rennert Chair of Aging Research, professor in the Departments of Medicine and Genetics, and member of the Diabetes Research Center and of the Divisions of Endocrinology & Diabetes and Geriatrics.
